本周，恒生港股通创新药指数上涨7.1%，中证港股通医药卫生综合指数上涨6.9%，中证创新药产业指数上涨5.3%，中证生 物科技主题指数上涨3.6%，沪深300医药卫生指数上涨3.4%。Wind数据显示，截至昨日，恒生创新药ETF（159316）本周 获近2亿元资金净流入，最新规模突破20亿元、创历史新高。 | | 恒生港股通 | 中证港股通 | 中证创新 | 中证生物 | 沪深300 | | --- | --- | --- | --- | --- | --- | | | 创新药指数 | 医药卫生综 | 药产业指 | 科技主题 | 矢药卫生 | | | | 合指数 | 150 | 指数 | 指数 | | 本周涨跌幅 | 7.1% | 6.9% | 5. 3% | 3.6% | 3.4% | | 指数估值 | 滚动市盈率 57.7倍 | 滚动市盈率 30. 7倍 | 滚动市盈率 57.3倍 | 滚动市盈率 62. 3倍 | 滚动市盘率 33.0倍 | | 指数估值 | 2023年7月 | 48. 5% | 88. 1% | 82. 1% | 60. 2% | | 分位 | 10日发布 | | | | | | 跟踪 ...

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative drug sector in the first half of the year, driven by successful collaborations, excellent clinical data, and supportive policies [1] - The China Securities report indicates that the innovative drug sector is expected to see a rapid increase in the commercial value of newly launched products due to national policies encouraging innovation [1] - The proportion of domestic innovative drugs in hospital products is anticipated to rise quickly, positioning this sector as one of the best growth segments [1] Group 2 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [4] - The index has shown a rolling price-to-earnings ratio of 59.2 times and an increase of 91.3% since its inception [5] - The biotechnology ETF tracks the China Biotechnology Theme Index, which includes up to 50 stocks related to gene diagnostics, biopharmaceuticals, and other human biotechnology [6] Group 3 - The healthcare ETF tracks the CSI 300 Healthcare Index, covering leading companies in the healthcare sector, including chemical pharmaceuticals, medical services, and medical devices [8] - The CSI 300 Healthcare Index has a rolling price-to-earnings ratio of 33.9 times and has increased by 65.7% since its inception [9]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 0.2%, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index fell by 0.1%. Conversely, the CSI Innovative Drug Industry Index, CSI Biotechnology Theme Index, and CSI 300 Medical and Health Index all increased by 0.1% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a growth of approximately 1 billion yuan in size over the past month, reaching a new historical high of nearly 2 billion yuan [1] Group 2 - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which focuses on leading innovative drug companies in Hong Kong, comprising no more than 40 stocks involved in innovative drug research, development, and production [2] - The CSI Hong Kong Stock Connect Medical and Health Comprehensive Index has been tracking since 2017 and includes 50 stocks from the medical device, biopharmaceutical, chemical drug, and other sectors within the Hong Kong Stock Connect [2] - The CSI Innovative Drug Industry Index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [2] - The CSI Biotechnology Theme Index targets leading biotechnology companies in the A-share market, including no more than 50 stocks involved in gene diagnosis, biopharmaceuticals, and other human biotechnology sectors [2] - The CSI 300 Medical and Health Index covers leading companies in the medical and health industry within the CSI 300 Index, encompassing various segments of the future health industry, including chemical pharmaceuticals, medical services, and medical devices [2]

Group 1 - The core indices related to the Hong Kong and A-share pharmaceutical sectors have shown significant increases, with the CSI Hong Kong Stock Connect Healthcare Index rising by 5.1%, the Hang Seng Stock Connect Innovative Drug Index by 4.8%, the CSI Innovative Drug Industry Index by 4.6%, the CSI Biotechnology Theme Index by 4%, and the CSI 300 Healthcare Index by 3.6% [1][5][9][13][15] - The Hang Seng Innovative Drug ETF (159316) has seen continuous capital inflow for four consecutive trading days, with its latest scale exceeding 1.8 billion yuan, marking a historical high [1] Group 2 - The CSI Hong Kong Stock Connect Healthcare Index focuses on leading stocks in the Hong Kong healthcare sector, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other healthcare-related companies [3] - The CSI Innovative Drug Industry Index targets leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [7] - The CSI Biotechnology Theme Index centers on leading biotechnology companies in the A-share market, including no more than 50 stocks related to gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [11] - The CSI 300 Healthcare Index encompasses leading companies in the A-share healthcare sector, covering chemical pharmaceuticals, medical services, medical devices, and other segments of the future health industry [15]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 3.6% at midday, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index rose by 3.5% [1] - The CSI Innovative Drug Industry Index saw a 2.2% increase, and the CSI Biotech Theme Index rose by 1.7% [1] - The CSI 300 Medical and Health Index increased by 1.9% [3] Group 2 - The Hang Seng Innovative Drug ETF (159316) had a trading volume exceeding 500 million yuan, with a net subscription of 54 million units [1] - The index tracked by the Hang Seng Innovative Drug ETF focuses on leading innovative drug companies in Hong Kong, consisting of no more than 40 stocks involved in innovative drug research and development [2] - The rolling price-to-earnings ratio for the Hang Seng Innovative Drug Index is 56.7 times [2] Group 3 - The CSI Hong Kong Stock Connect Medical and Health Comprehensive Index includes 50 stocks from the medical device, biopharmaceutical, and chemical drug sectors [2] - The rolling price-to-earnings ratio for this index is 29.2 times, with a 46.2% increase since its inception in 2017 [2] Group 4 - The CSI Innovative Drug Industry Index focuses on leading innovative drug companies in A-shares, consisting of no more than 50 stocks involved in innovative drug research and development [2] - The rolling price-to-earnings ratio for this index is 52.8 times, with a 79.8% increase since its launch in 2019 [2] Group 5 - The CSI Biotech Theme Index includes up to 50 stocks involved in gene diagnostics, biopharmaceuticals, and other human biotechnology [2] - The rolling price-to-earnings ratio for this index is 58.3 times, with a 72.4% increase since its inception in 2015 [2] Group 6 - The CSI 300 Medical and Health Index covers leading companies in the medical and health sector, including chemical pharmaceuticals, medical services, and medical devices [3] - The rolling price-to-earnings ratio for this index is 32.6 times, with a 58.0% increase since its inception in 2007 [3]

Group 1 - The Shanghai and Shenzhen 300 Pharmaceutical Health Index decreased by 0.3% at midday, while the CSI Biotech Theme Index fell by 0.4%, the CSI Innovative Drug Industry Index dropped by 0.6%, the CSI Hong Kong Stock Connect Pharmaceutical Health Comprehensive Index declined by 1.3%, and the Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 1.6% [1][2][3] - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of 14 million units during the half-day trading session [1][2] Group 2 - The Hang Seng Innovative Drug Index focuses on leading innovative drug companies in Hong Kong, consisting of no more than 40 stocks involved in innovative drug research, development, and production [2] - The CSI Hong Kong Stock Connect Pharmaceutical Health Comprehensive Index targets leading companies in the Hong Kong medical and health sector, comprising 50 stocks from medical devices, biopharmaceuticals, and chemical drugs [2] - The CSI Innovative Drug Industry Index concentrates on leading innovative drug companies in A-shares, made up of no more than 50 stocks primarily engaged in innovative drug research and development [2] - The CSI Biotech Theme Index focuses on leading biotech companies in A-shares, including no more than 50 stocks involved in gene diagnostics, biopharmaceuticals, and blood products [2]

Group 1 - The article discusses various ETFs tracking innovative pharmaceutical indices in Hong Kong and mainland China, highlighting their focus on leading companies in the innovative drug sector [1] - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which consists of no more than 40 stocks involved in innovative drug research, development, and production [1] - The Hong Kong Stock Connect Medical ETF tracks the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index, comprising 50 stocks from the medical device, biopharmaceutical, chemical drug, and other healthcare sectors [1] Group 2 - The E Fund Innovative Drug ETF tracks the CSI Innovative Drug Industry Index, focusing on leading companies in the A-share innovative drug sector, consisting of no more than 50 stocks involved in innovative drug research and development [1] - The performance metrics of these indices show varying changes, with the Hang Seng Innovative Drug ETF experiencing a decline of 0.1% and the Hong Kong Stock Connect Medical ETF increasing by 0.7% [1] - The E Fund Innovative Drug ETF has seen an increase of 2.7% since its inception, with a rolling price-to-earnings ratio of 54.9 times and an 83.7% valuation percentile since its launch [1]

Group 1 - The China Consumer Electronics Theme Index rose by 2.6%, the China Internet of Things Theme Index increased by 2.4%, the National Robot Industry Index went up by 2.0%, and the China Smart Electric Vehicle Index saw a rise of 1.1% [1] - The E Fund Robot ETF (159530) experienced a net inflow of 950 million yuan last week and received an additional net subscription of 76 million units today, bringing its latest scale to 5.93 billion yuan, a record high [1]

Group 1 - The core viewpoint of the news highlights the positive performance of various healthcare indices, with the CSI Hong Kong Stock Connect Healthcare Index rising by 2.4%, the Hang Seng Hong Kong Stock Connect Innovative Drug Index increasing by 2.3%, and the CSI Biotech Theme Index up by 0.8% [1][2] - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of 16 million units today, bringing its total size to over 1.5 billion yuan, marking a historical high [1][2] - The indices mentioned focus on leading companies in the healthcare and innovative drug sectors, with the Hang Seng Innovative Drug Index comprising no more than 40 stocks involved in innovative drug research and development [2][3] Group 2 - The CSI Hong Kong Stock Connect Healthcare Index includes 50 stocks from the healthcare sector, covering medical devices, biopharmaceuticals, and chemical drugs, with a rolling price-to-earnings ratio of 30.4 times [2][3] - The CSI Innovative Drug Industry Index focuses on A-share innovative drug leaders, consisting of no more than 50 companies engaged in innovative drug research, with a rolling price-to-earnings ratio of 53.7 times [2][3] - The CSI Biotech Theme Index targets A-share biotech leaders, including companies involved in gene diagnostics and biopharmaceuticals, with a rolling price-to-earnings ratio of 56.2 times [2][3]

Core Viewpoint - The pharmaceutical and healthcare indices in the Chinese stock market have shown positive performance, with significant inflows into innovative drug ETFs, indicating a growing interest in the sector [1][2]. Group 1: Index Performance - The CSI 300 Pharmaceutical and Healthcare Index increased by 1.2% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Comprehensive Index rose by 1.1% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Index and the CSI Biotechnology Theme Index both saw a rise of 0.7% [1]. - The CSI Innovative Drug Industry Index experienced a slight increase of 0.01% [1]. Group 2: ETF Activity - The Hang Seng Innovative Drug ETF (159316) recorded a net subscription of 11 million units in the first half of the day, bringing its total size to over 1.5 billion yuan, a historical high [1]. - The index tracked by the Hang Seng Innovative Drug ETF focuses on leading innovative drug companies in the Hong Kong stock market, comprising no more than 40 stocks involved in innovative drug research, development, and production [2]. - The rolling price-to-earnings ratio for the Hang Seng Innovative Drug Index is currently at 56.2 times [2]. Group 3: Valuation Metrics - The rolling price-to-earnings ratio for the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Comprehensive Index stands at 30.4 times, with a valuation percentile of 48.1% since 2017 [2]. - The rolling price-to-earnings ratio for the CSI Innovative Drug Industry Index is not specified, but it focuses on A-share innovative drug leaders, comprising no more than 50 stocks involved in innovative drug research and development [2].